1 day ago · The Company generated $10.4 billion of free cash flow for the full year 2024 versus $7.4 billion in 2023. The Company's fourth quarter 2024 dividend of $2.25 per share was declared on October 25, 2024, and was paid on December 9, 2024, to all stockholders of record as of November 18, 2024, representing a 6% increase from the same period in 2023.

1 day ago · The Company's fourth quarter 2024 dividend of $2.25 per share was declared on October 25, 2024, and was paid on December 9, 2024, to all stockholders of record as of November 18, 2024 ...

Dec 6, 2024 · Today, Amgen shared its 2024 fourth quarter and full year earnings report. Amgen’s more than 27,000 employees are united by our mission to serve patients. We harness the best of biology and technology to fight the world’s toughest diseases, and make people’s lives easier, fuller, and longer.

15 hours ago · Amgen Inc (AMGN) reports a 19% revenue increase, driven by strong product sales and strategic international expansions, despite facing market challenges. ... Amgen Inc (AMGN) Q4 2024 Earnings Call ...

1 day ago · Amgen (NASDAQ: AMGN) Q4 2024 Earnings Call Feb 04, 2025, 4:30 p.m. ET. Contents: Prepared Remarks; ... This concludes our 2024 Q4 and full yearearnings call [Operator signoff] Duration: 0 minutes.

Amgen, Inc. (NASDAQ:AMGN) Q4 2024 Earnings Conference Call February 4, 2025 4:30 PM ETCompany ParticipantsJustin Claeys - VP, IRRobert Bradway - Chairman,...

Amgen (NASDAQ: AMGN). Q4 2024 Earnings Call. Feb 04, 2025, 4:30 p.m. ET. Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here.

Feb 6, 2024 · "Our marketed products are reaching many more patients around the world, and we anticipate more than a dozen significant pipeline milestones in 2024." Key results include: For the fourth quarter, total revenues increased 20% to $8.2 …

Dec 5, 2024 · amgen announces webcast of 2024 fourth quarter and full year financial results NEWS RELEASE 01.17.2025 FDA APPROVES LUMAKRAS® (SOTORASIB) IN COMBINATION WITH VECTIBIX® (PANITUMUMAB) FOR CHEMOREFRACTORY KRAS G12C-MUTATED METASTATIC COLORECTAL CANCER

9 hours ago · For the entire year 2024, Amgen surged 19% to bring in $33.4 billion. ... Analysts at BMO Capital Markets wrote in an investor note on Tuesday that Amgen’s Q4 performance “illustrated that mature products like Repatha still have some runway for growth which goes under the radar because of a heavier focus on its more recent launches.” ...